Medically reviewed by the Celva medical team · June 2026
Durability,
and the decay curve.
How long the effect of IV MSC therapy actually lasts, when it starts to fade, and how to read whether a maintenance infusion makes sense, or doesn't yet.
Where most patients report best-achieved response after a loading infusion.
Response holds. This is the window where maintenance decisions are made.
Gradual return toward baseline for many. Individual curves vary.
What the response
curve looks like.
A loading infusion doesn't "last forever", and it doesn't fade in a month. Between months three and twelve most patients sit on a plateau. After twelve months, the curve begins trending back toward baseline. The rate of decay varies by person.
Patients with higher baseline inflammatory burden often experience a steeper initial response and a shorter plateau. Patients with lower baseline tend toward a flatter, longer durability curve.
This is why maintenance is reviewed at twelve months rather than scheduled reflexively at six. The response tells us when to intervene again.
Infusion
Baseline. Biodistribution begins.
Rising phase
Early signals emerge, sleep, recovery, inflammation markers.
Peak window
Best-achieved response for most patients.
Plateau
Response holds. Stability is the signal.
Decay
Gradual return toward baseline begins for many. Maintenance considered.
Why some
hold longer.
Baseline inflammation
Higher baseline often means steeper initial response, shorter plateau. Lower baseline tends toward longer durability.
- CRP / ESR trends
- Chronic inflammatory load
- Autoimmune-adjacent profile
Lifestyle load
Sleep, training, nutrition, and stress compound. The better the foundation, the longer the response holds.
- Sleep duration / quality
- Training volume & load
- Metabolic health
Age & recovery capacity
Younger patients with intact recovery biology often see longer plateaus. The decay curve steepens with age.
- Age decile
- Hormonal status
- Resident tissue biology
When a repeat
makes sense.
Maintenance is a decision made at follow-up review by the physician team, not a standing subscription. The signal is the response curve, not the calendar.
When the response is clearly fading, a maintenance infusion is appropriate, and each one builds on the last. When it is holding, you have two honest options: hold and reassess, or, if your goal is to keep building, stack the next dose on the plateau so the gains compound instead of waiting for them to fade. The physician team walks you through both.
Clear decay markers
Symptoms returning. Biomarkers trending back toward pre-infusion values. Maintenance reasonable.
Still on plateau
Response holding, no clear decay. Reassess later, or stack a dose on the plateau to build further if maximizing the gain is your goal.
Life event or major load
Surgery, prolonged illness, major training block. Pre-emptive maintenance may make sense, by indication.
Durability
questions.
Q.01What's the longest anyone has held a response?
Q.02Can I measure durability objectively?
Q.03What if I'm not feeling anything fade yet at my next review?
Keep
reading.
Maintenance,
by indication.
Follow-up is structured around your actual response. No monthly subscriptions. No pre-scheduled infusions without a clinical reason. The physician team discusses what's realistic for your case during review.